Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody
Open Access
- 1 November 2010
- journal article
- research article
- Published by Elsevier BV in Online Journal of Public Health Informatics
- Vol. 285 (46), 36149-36157
- https://doi.org/10.1074/jbc.m110.134031
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Down-Regulation of the Met Receptor Tyrosine Kinase by Presenilin-dependent Regulated Intramembrane ProteolysisMolecular Biology of the Cell, 2009
- “Active” Cancer Immunotherapy by Anti-Met Antibody Gene TransferCancer Research, 2008
- When binding is enough: nonactivating antibody formatsCurrent Opinion in Immunology, 2008
- Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis CNature Biotechnology, 2007
- A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G"Protein Engineering, Design and Selection", 2007
- c-Met is essential for wound healing in the skinThe Journal of cell biology, 2007
- Agonist Met antibodies define the signalling threshold required for a full mitogenic and invasive program of Kaposi’s Sarcoma cellsBiochemical and Biophysical Research Communications, 2005
- High-throughput antibody productionCurrent Opinion in Chemical Biology, 2005
- Scatter-factor and semaphorin receptors: cell signalling for invasive growthNature Reviews Cancer, 2002
- Hepatocyte Growth Factor Enhances Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and in VivoThe American Journal of Pathology, 2001